17 Dec 2019 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams discusses the funding package and resumption plan for the Granville Tin Project and plans for Granville to be a foundation asset in a proposed IPO.
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
16 Dec 2019 - Openpay Group (ASX:OPY) CEO & MD, Michael Eidel talks about its business model, size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
05 Dec 2019 - Memphasys Limited (ASX:MEM) Executive Chairman, Alison Coutts talks about progress with the company's human assisted reproductive device for the separation of sperm cells in IVF clinics.
05 Dec 2019 - Bio-Gene Technology Limited (ASX:BGT) CEO, Richard Jagger discusses the company's novel suite of insecticides, progress with trials and market opportunity.
04 Dec 2019 - Xref Limited (ASX:XF1) CEO & Co-Founder, Lee-Martin Seymour, talks about the company's candidate reference checking solution for HR departments, partner integration and expansion.
04 Dec 2019 - DigitalX Limited (ASX:DCC) Executive Director Leigh Travers talks about the growing interest in blockchain solutions for real world problems and the company's new DigitalX Bitcoin Fund.
04 Dec 2019 - Altech Chemicals Limited (ASX:ATC) Engineering Manager, Mark Griffiths discusses progress with the company's HPA (High Purity Alumina) plant in Malaysia, demand projections, project financing and economics.
03 Dec 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company's Phase 1b clinical DARRT-1 trial for its lead product candidate, Veyonda, with low-dose radiotherapy.
